164 related articles for article (PubMed ID: 34978892)
1. Measurements of 5,6-Orthoquinone, a Surrogate for the Presumed Active Primaquine Metabolite 5-Hydroxyprimaquine, in the Urine of Cambodian Adults.
Vanachayangkul P; Sea D; Wojnarski M; Sok S; Kodchakorn C; Ta-Aksorn W; Hom S; Ittiverakul M; Kuntawunginn W; Arsanok M; Buathong N; Heng TK; Nareth K; Nou S; Chandara S; Ly S; Oung P; Vesely B; Bennett J; Reichard G; Pybus B; Lanteri C; Saunders D; Fukuda M; Smith P; Dysoley L; Rekol H; Waters NC; Spring M
Antimicrob Agents Chemother; 2022 Mar; 66(3):e0182121. PubMed ID: 34978892
[TBL] [Abstract][Full Text] [Related]
2. Determination of Cytochrome P450 Isoenzyme 2D6 (CYP2D6) Genotypes and Pharmacogenomic Impact on Primaquine Metabolism in an Active-Duty US Military Population.
Spring MD; Sousa JC; Li Q; Darko CA; Morrison MN; Marcsisin SR; Mills KT; Potter BM; Paolino KM; Twomey PS; Moon JE; Tosh DM; Cicatelli SB; Froude JW; Pybus BS; Oliver TG; McCarthy WF; Waters NC; Smith PL; Reichard GA; Bennett JW
J Infect Dis; 2019 Oct; 220(11):1761-1770. PubMed ID: 31549155
[TBL] [Abstract][Full Text] [Related]
3. Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent Plasmodium vivax Malaria.
Baird JK; Louisa M; Noviyanti R; Ekawati L; Elyazar I; Subekti D; Chand K; Gayatri A; Instiaty ; Soebianto S; Crenna-Darusallam C; Djoko D; Hasto BD; Meriyenes D; Wesche D; Nelwan EJ; Sutanto I; Sudoyo H; Setiabudy R
JAMA Netw Open; 2018 Aug; 1(4):e181449. PubMed ID: 30646129
[TBL] [Abstract][Full Text] [Related]
4. Multiple relapses of Plasmodium vivax malaria acquired from West Africa and association with poor metabolizer CYP2D6 variant: a case report.
He X; Pan M; Zeng W; Zou C; Pi L; Qin Y; Zhao L; Qin P; Lu Y; Baird JK; Huang Y; Cui L; Yang Z
BMC Infect Dis; 2019 Aug; 19(1):704. PubMed ID: 31399061
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of CYP2D6 Genotypes and Predicted Phenotypes in a Cohort of Cambodians at High Risk for Infections with
Spring MD; Lon C; Sok S; Sea D; Wojnarski M; Chann S; Kuntawunginn W; Kheang Heng T; Nou S; Arsanok M; Sriwichai S; Vanachayangkul P; Lin JT; Manning JE; Jongsakul K; Pichyangkul S; Satharath P; Smith PL; Dysoley L; Saunders DL; Waters NC
Am J Trop Med Hyg; 2020 Aug; 103(2):756-759. PubMed ID: 32394887
[TBL] [Abstract][Full Text] [Related]
6. Several Plasmodium vivax relapses after correct primaquine treatment in a patient with impaired cytochrome P450 2D6 function.
Martin Ramírez A; Lombardia González C; Soler Maniega T; Gutierrez Liarte Á; Domingo García D; Lanza Suárez M; Bernal Fernández MJ; Rubio JM
Malar J; 2020 Jul; 19(1):259. PubMed ID: 32680522
[TBL] [Abstract][Full Text] [Related]
7. Four Times of Relapse of Plasmodium vivax Malaria Despite Primaquine Treatment in a Patient with Impaired Cytochrome P450 2D6 Function.
Choi S; Choi H; Park SY; Kwak YG; Song JE; Shin SY; Baek JH; Shin HI; Oh HS; Kim YC; Yeom JS; Han JH; Kim MJ
Korean J Parasitol; 2022 Feb; 60(1):39-43. PubMed ID: 35247953
[TBL] [Abstract][Full Text] [Related]
8. Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial.
St Jean PL; Xue Z; Carter N; Koh GC; Duparc S; Taylor M; Beaumont C; Llanos-Cuentas A; Rueangweerayut R; Krudsood S; Green JA; Rubio JP
Malar J; 2016 Feb; 15():97. PubMed ID: 26888075
[TBL] [Abstract][Full Text] [Related]
9. Novel Insights into Plasmodium vivax Therapeutic Failure: CYP2D6 Activity and Time of Exposure to Malaria Modulate the Risk of Recurrence.
Silvino ACR; Kano FS; Costa MA; Fontes CJF; Soares IS; de Brito CFA; Carvalho LH; Sousa TN
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32122891
[No Abstract] [Full Text] [Related]
10. Enantioselective metabolism of primaquine by human CYP2D6.
Fasinu PS; Tekwani BL; Nanayakkara NP; Avula B; Herath HM; Wang YH; Adelli VR; Elsohly MA; Khan SI; Khan IA; Pybus BS; Marcsisin SR; Reichard GA; McChesney JD; Walker LA
Malar J; 2014 Dec; 13():507. PubMed ID: 25518709
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P450 2D6 profiles and their relationship with outcomes of primaquine anti-relapse therapy in Australian Defence Force personnel deployed to Papua New Guinea and East Timor.
Chen N; Dowd S; Gatton ML; Auliff A; Edstein MD; Cheng Q
Malar J; 2019 Apr; 18(1):140. PubMed ID: 30999967
[TBL] [Abstract][Full Text] [Related]
12. CYP2D6 activity and the risk of recurrence of Plasmodium vivax malaria in the Brazilian Amazon: a prospective cohort study.
Brasil LW; Rodrigues-Soares F; Santoro AB; Almeida ACG; Kühn A; Ramasawmy R; Lacerda MVG; Monteiro WM; Suarez-Kurtz G
Malar J; 2018 Feb; 17(1):57. PubMed ID: 29390987
[TBL] [Abstract][Full Text] [Related]
13. Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms.
Baird JK; Battle KE; Howes RE
Malar J; 2018 Jan; 17(1):42. PubMed ID: 29357870
[TBL] [Abstract][Full Text] [Related]
14. An increase in urinary primaquine and a reduction in urinary primaquine-5,6-orthoquinone in the Thai population with CYP2D6 reduced enzyme function.
Pookmanee W; Thongthip S; Mungthin M; Sukasem C; Tankanitlert J; Chariyavilaskul P; Wittayalertpanya S
Heliyon; 2024 Jan; 10(2):e24351. PubMed ID: 38293439
[TBL] [Abstract][Full Text] [Related]
15.
Pett H; Bradley J; Okebe J; Dicko A; Tiono AB; Gonçalves BP; Stone W; Chen I; Lanke K; Neuvonen M; Mustaniemi AL; Eziefula AC; Gosling R; D'Alessandro U; Drakeley C; Niemi M; Bousema T
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31383656
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome P450 2D6 profiles and anti-relapse efficacy of tafenoquine against
Dowd S; Chen N; Gatton ML; Edstein MD; Cheng Q
Antimicrob Agents Chemother; 2023 Dec; 67(12):e0101423. PubMed ID: 37971260
[No Abstract] [Full Text] [Related]
17. Association between CYP2D6 phenotype and recurrence of Plasmodium vivax infection in south Korean patients.
Choi S; Choi H; Park SY; Kwak YG; Song JE; Shin SY; Baek JH; Shin HI; Cho SH; Lee SE; Kwon JR; Park S; Kim M; Oh HS; Kim YC; Kim MJ; Yeom JS
Malar J; 2022 Oct; 21(1):289. PubMed ID: 36217154
[TBL] [Abstract][Full Text] [Related]
18. Effects of CYP2D6 genotypes on Plasmodium vivax recurrence after primaquine treatment: A meta-analysis.
Park YA; Park KH; Yoon HY; Yee J; Gwak HS
Travel Med Infect Dis; 2022; 48():102333. PubMed ID: 35452835
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics/pharmacodynamics of chloroquine and artemisinin-based combination therapy with primaquine.
Daher A; Aljayyoussi G; Pereira D; Lacerda MVG; Alexandre MAA; Nascimento CT; Alves JC; da Fonseca LB; da Silva DMD; Pinto DP; Rodrigues DF; Silvino ACR; de Sousa TN; de Brito CFA; Ter Kuile FO; Lalloo DG
Malar J; 2019 Sep; 18(1):325. PubMed ID: 31547827
[TBL] [Abstract][Full Text] [Related]
20. Impact of CYP2D6 Genetic Variation on Radical Cure of Plasmodium vivax Malaria.
Suarez-Kurtz G
Clin Pharmacol Ther; 2021 Sep; 110(3):595-598. PubMed ID: 34042179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
